Publications & News

WilmerHale Honored with BADC Quality of Life Award

September 7, 2016

The Bar Association of the District of Columbia has selected WilmerHale to receive its 19th Annual Constance L. Belfiore Quality of Life Award, which honors law firms and legal departments that recognize the importance of quality of life as well as professional excellence.

WilmerHale Honored with BADC Quality of Life Award

Publications

September 27, 2016

Agencies Chart the Future of US Offshore Wind Development

The US Department of Energy and US Department of the Interior recently announced an updated national strategy to facilitate the responsible development of offshore wind...

Read More


September 23, 2016

Key Differences Between CFTC and SEC Final Business Conduct Standards and Related Cross-Border Requirements

An article by Paul Architzel, Dan Berkovitz, Gail Bernstein, Seth Davis and Ted Serafini, published in the Journal of Investment Compliance in September 2016, analyzes...

Read More


September 21, 2016

Copyright and Trademark Case Review: RunDMC, Stem Cells and Pirates

WilmerHale compiles lists of precedential and informative opinions that raise copyright and trademark law issues. The following is a consolidated list of those opinions...

Read More


News

September 22, 2016

Law Week Colorado Honors Natalie Hanlon Leh and Andrew Spielman Among the Top Lawyers in Colorado

Partners Natalie Hanlon Leh and Andrew Spielman have been named to Law Week Colorado's annual list of Barrister's Best, featuring the top lawyers in the state by...Read More


September 22, 2016

WilmerHale Advises Agios Pharmaceuticals in $173M Public Offering and Full Exercise of Option to Purchase Additional Shares

The WilmerHale team was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Mhairi Immermann and Associate Brett Bromann.Read More


September 22, 2016

WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or...Read More